

Supplementary Table 2. Age-adjusted incidence rate* of cancer,† aged <20 years, by type and U.S. Census region§ — United States,¶ 2003–2014

Cancer type by ICCC group	U.S. Census region§									
	Total		Northeast		Midwest		South		West	
	No.	Rate (95% CI)	No.	Rate (95% CI)	No.	Rate (95% CI)	No.	Rate (95% CI)	No.	Rate (95% CI)
I Leukemias, myeloproliferative & myelodysplastic diseases	44,814	45.7 (45.3–46.1)	7,809	47.0 (46.0–48.1)	9,486	44.0 (43.1–44.8)	16,062	43.6 (42.9–44.3)	11,457	49.9 (49.0–50.8)
I(a) Lymphoid leukemias	32,394	33.2 (32.8–33.5)	5,605	34.0 (33.1–34.9)	6,863	31.9 (31.1–32.7)	11,288	30.7 (30.1–31.3)	8,638	37.7 (36.9–38.5)
I(b) Acute myeloid leukemias	7,426	7.5 (7.4–7.7)	1,270	7.5 (7.1–7.9)	1,616	7.4 (43.1–7.8)	2,702	7.3 (7.0–7.6)	1,838	8.0 (7.6–8.3)
I(c) Chronic myeloproliferative diseases	2,301	2.3 (2.2–2.4)	466	2.7 (2.5–3.0)	407	1.8 (43.1–2.0)	1,000	2.7 (2.5–2.9)	428	1.9 (1.7–2.0)
I(d) Myelodysplastic syndrome and other myeloproliferative	1,366	1.4 (1.3–1.5)	249	1.5 (1.3–1.7)	333	1.5 (43.1–1.7)	491	1.3 (1.2–1.5)	293	1.3 (1.1–1.4)
I(e) Unspecified and other specified leukemias	1,327	1.4 (1.3–1.4)	219	1.3 (1.1–1.5)	267	1.2 (43.1–1.4)	581	1.6 (1.5–1.7)	260	1.1 (1.0–1.3)
II Lymphomas and reticuloendothelial neoplasms	26,016	26.2 (25.9–26.5)	5,230	30.0 (29.2–30.9)	5,830	26.4 (43.1–27.1)	9,223	25.0 (24.5–25.5)	5,733	24.9 (24.3–25.6)
II(a) Hodgkin lymphomas	12,185	12.2 (11.9–12.4)	2,585	14.5 (14.0–15.1)	2,811	12.6 (43.1–13.0)	4,194	11.3 (11.0–11.7)	2,595	11.2 (10.8–11.7)
II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma)	8,630	8.7 (8.5–8.9)	1,748	10.1 (9.7–10.6)	1,821	8.3 (43.1–8.7)	3,142	8.5 (8.3–8.9)	1,919	8.4 (8.0–8.8)
II(c) Burkitt lymphoma	2,377	2.4 (2.3–2.5)	460	2.7 (2.5–3.0)	576	2.7 (43.1–2.9)	812	2.2 (2.1–2.4)	529	2.3 (2.1–2.5)
II(d) Miscellaneous lymphoreticular neoplasms	2,499	2.6 (2.5–2.7)	386	2.4 (2.1–2.6)	555	2.6 (43.1–2.8)	921	2.5 (2.3–2.7)	637	2.8 (2.6–3.0)
II(e) Unspecified lymphomas	325	0.3 (0.3–0.4)	51	0.3 (0.2–0.4)	67	0.3 (43.1–0.4)	154	0.4 (0.4–0.5)	53	0.2 (0.2–0.3)
III CNS and misc intracranial and intraspinal neoplasms	30,217	30.9 (30.6–31.3)	5,732	34.4 (33.5–35.3)	6,763	31.3 (43.1–32.1)	11,251	30.7 (30.1–31.3)	6,471	28.3 (27.6–29.0)
III(a) Ependymomas and choroid plexus tumor	2,561	2.6 (2.5–2.7)	440	2.7 (2.4–2.9)	576	2.7 (43.1–2.9)	931	2.5 (2.4–2.7)	614	2.7 (2.5–2.9)
III(b) Astrocytomas	15,497	15.8 (15.6–16.1)	3,065	18.4 (17.7–19.0)	3,526	16.3 (43.1–16.9)	5,657	15.4 (15.0–15.9)	3,249	14.2 (13.7–14.7)
III(c) Intracranial and intraspinal embryonal tumors	5,906	6.1 (5.9–6.2)	959	5.8 (5.5–6.2)	1,328	6.2 (43.1–6.5)	2,205	6.0 (5.8–6.3)	1,414	6.2 (5.9–6.5)
III(d) Other gliomas	5,169	5.3 (5.2–5.4)	1,076	6.4 (6.0–6.8)	1,115	5.2 (43.1–5.5)	1,959	5.4 (5.1–5.6)	1,019	4.5 (4.2–4.8)
III(e) Other specified intracranial/intraspinal neoplasms	622	0.6 (0.6–0.7)	124	0.7 (0.6–0.9)	139	0.6 (43.1–0.8)	247	0.7 (0.6–0.8)	112	0.5 (0.4–0.6)
III(f) Unspecified intracranial and intraspinal neoplasms	462	0.5 (0.4–0.5)	68	0.4 (0.3–0.5)	79	0.4 (43.1–0.5)	252	0.7 (0.6–0.8)	63	0.3 (0.2–0.4)
IV Neuroblastoma and other peripheral nervous cell tumors	8,308	8.5 (8.3–8.6)	1,549	9.5 (9.1–10.0)	1,965	9.2 (43.1–9.6)	3,058	8.2 (7.9–8.5)	1,736	7.5 (7.1–7.8)
IV(a) Neuroblastoma and ganglioneuroblastoma	8,076	8.2 (8.1–8.4)	1,509	9.3 (8.9–9.8)	1,913	9.0 (43.1–9.4)	2,969	8.0 (7.7–8.3)	1,685	7.2 (6.9–7.6)
IV(b) Other peripheral nervous cell tumors	232	0.2 (0.2–0.3)	40	0.2 (0.2–0.3)	52	0.2 (43.1–0.3)	89	0.2 (0.2–0.3)	51	0.2 (0.2–0.3)
V Retinoblastoma	3,121	3.2 (3.1–3.3)	529	3.3 (3.0–3.6)	632	3.0 (43.1–3.2)	1,204	3.2 (3.0–3.4)	756	3.2 (3.0–3.5)
VI Renal tumors	6,698	6.8 (6.7–7.0)	1,151	7.1 (6.7–7.5)	1,484	6.9 (43.1–7.3)	2,646	7.1 (6.9–7.4)	1,417	6.1 (5.8–6.5)
VI(a) Nephroblastoma and other nonepithelial renal tumors	6,070	6.2 (6.1–6.4)	1,042	6.4 (6.1–6.8)	1,352	6.3 (43.1–6.7)	2,365	6.4 (6.1–6.6)	1,311	5.7 (5.4–6.0)
VI(b) Renal carcinomas	594	0.6 (0.6–0.7)	109	0.6 (0.5–0.8)	126	0.6 (43.1–0.7)	258	0.7 (0.6–0.8)	101	0.4 (0.4–0.5)
VI(c) Unspecified malignant renal tumors	34	0.0 (0.0–0.1)	—	—	—	—	23	0.1 (0.0–0.1)	—	—
VII Hepatic tumors	2,305	2.3 (2.2–2.4)	419	2.5 (2.3–2.8)	486	2.3 (43.1–2.5)	818	2.2 (2.1–2.4)	582	2.5 (2.3–2.7)
VII(a) Hepatoblastoma	1,706	1.7 (1.7–1.8)	298	1.8 (1.6–2.1)	367	1.7 (43.1–1.9)	599	1.6 (1.5–1.7)	442	1.9 (1.7–2.1)
VII(b) Hepatic carcinomas	575	0.6 (0.5–0.6)	118	0.7 (0.6–0.8)	116	0.5 (43.1–0.6)	202	0.6 (0.5–0.6)	139	0.6 (0.5–0.7)
VII(c) Unspecified malignant hepatic tumors	24	0.0 (0.0–0.0)	—	—	—	—	17	0.1 (0.0–0.1)	—	—
VIII Malignant bone tumors	8,472	8.6 (8.4–8.8)	1,571	9.1 (8.6–9.6)	1,816	8.3 (43.1–8.6)	3,133	8.5 (8.2–8.8)	1,952	8.5 (8.2–8.9)
VIII(a) Osteosarcomas	4,751	4.8 (4.7–4.9)	818	4.7 (4.4–5.1)	1,031	4.7 (43.1–5.0)	1,774	4.8 (4.6–5.1)	1,128	4.9 (4.6–5.2)
VIII(b) Chondrosarcomas	322	0.3 (0.3–0.4)	75	0.4 (0.3–0.5)	69	0.3 (43.1–0.4)	115	0.3 (0.3–0.4)	63	0.3 (0.2–0.4)
VIII(c) Ewing tumor and related sarcomas of bone	2,784	2.8 (2.7–2.9)	542	3.2 (2.9–3.4)	615	2.8 (43.1–3.0)	993	2.7 (2.5–2.9)	634	2.8 (2.6–3.0)
VIII(d) Other specified malignant bone tumors	428	0.4 (0.4–0.5)	99	0.6 (0.5–0.7)	72	0.3 (43.1–0.4)	160	0.4 (0.4–0.5)	97	0.4 (0.3–0.5)
VIII(e) Unspecified malignant bone tumors	187	0.2 (0.2–0.2)	37	0.2 (0.2–0.3)	29	0.1 (43.1–0.2)	91	0.3 (0.2–0.3)	30	0.1 (0.1–0.2)
IX Soft tissue and other extraosseous sarcomas	11,530	11.7 (11.5–11.9)	2,115	12.4 (11.9–13.0)	2,519	11.5 (43.1–12.0)	4,259	11.6 (11.2–11.9)	2,637	11.5 (11.0–11.9)
IX(a) Rhabdomyosarcomas	4,495	4.6 (4.5–4.7)	804	4.9 (4.5–5.2)	979	4.5 (43.1–4.8)	1,679	4.6 (4.4–4.8)	1,033	4.5 (4.2–4.8)
IX(b) Fibrosarcomas, peripheral nerve & other fibrous	1,217	1.2 (1.2–1.3)	221	1.3 (1.1–1.5)	295	1.3 (43.1–1.5)	428	1.2 (1.1–1.3)	273	1.2 (1.0–1.3)
IX(c) Kaposi sarcoma	49	0.1 (0.0–0.1)	—	—	—	—	23	0.1 (0.0–0.1)	—	—
IX(d) Other specified soft tissue sarcomas	4,544	4.6 (4.5–4.7)	850	4.9 (4.6–5.3)	975	4.4 (43.1–4.7)	1,629	4.4 (4.2–4.6)	1,090	4.7 (4.5–5.0)
IX(e) Unspecified soft tissue sarcomas	1,225	1.2 (1.2–1.3)	227	1.3 (1.2–1.5)	262	1.2 (43.1–1.4)	500	1.4 (1.2–1.5)	236	1.0 (0.9–1.2)
X Germ cell & trophoblastic tumors & neoplasms of gonads	10,992	11.0 (10.7–11.2)	1,906	10.8 (10.3–11.3)	2,445	11.0 (43.1–11.4)	3,735	10.0 (9.7–10.4)	2,906	12.5 (12.0–13.0)
X(a) Intracranial & intraspinal germ cell tumors	1,626	1.7 (1.6–1.7)	287	1.7 (1.5–1.9)	337	1.5 (43.1–1.7)	551	1.5 (1.4–1.6)	451	2.0 (1.8–2.2)
X(b) Extracranial & extragonadal germ cell tumors	1,431	1.4 (1.4–1.5)	251	1.5 (1.3–1.7)	294	1.4 (43.1–1.5)	531	1.4 (1.3–1.5)	355	1.5 (1.4–1.7)
X(c) Malignant gonadal germ cell tumors	7,189	7.1 (7.0–7.3)	1,235	6.9 (6.5–7.3)	1,653	7.3 (43.1–7.7)	2,370	6.4 (6.1–6.6)	1,931	8.3 (7.9–8.7)
X(d) Gonadal carcinomas	429	0.4 (0.4–0.5)	76	0.4 (0.3–0.5)	101	0.5 (43.1–0.6)	147	0.4 (0.3–0.5)	105	0.5 (0.4–0.6)
X(e) Other and unspecified malignant gonadal tumors	317	0.3 (0.3–0.4)	57	0.3 (0.3–0.4)	60	0.3 (43.1–0.4)	136	0.4 (0.3–0.4)	64	0.3 (0.2–0.4)
XI Other malignant epithelial neoplasms and melanomas††	17,916	17.8 (17.6–18.1)	3,734	20.9 (20.2–21.6)	4,083	18.2 (43.1–18.8)	6,126	16.5 (16.1–16.9)	3,973	17.1 (16.6–17.7)
XI(a) Adrenocortical carcinomas	208	0.2 (0.2–0.2)	34	0.2 (0.1–0.3)	51	0.2 (43.1–0.3)	77	0.2 (0.2–0.3)	46	0.2 (0.2–0.3)
XI(b) Thyroid carcinomas	7,866	7.8 (7.6–8.0)	1,854	10.3 (9.9–10.8)	1,734	7.7 (43.1–8.1)	2,481	6.7 (6.4–7.0)	1,797	7.7 (7.4–8.1)
XI(c) Nasopharyngeal carcinomas	557	0.6 (0.5–0.6)	93	0.5 (0.4–0.6)	110	0.5 (43.1–0.6)	255	0.7 (0.6–0.8)	99	0.4 (0.4–0.5)
XI(d) Malignant melanomas	4,853	4.8 (4.7–5.0)	916	5.2 (4.8–5.5)	1,157	5.2 (43.1–5.5)	1,693	4.6 (4.3–4.8)	1,087	4.7 (4.4–5.0)
XI(f) Other and unspecified carcinomas	4,349	4.3 (4.2–4.5)	828	4.7 (4.3–5.0)	1,010	4.5 (43.1–4.8)	1,583	4.3 (4.1–4.5)	928	4.0 (3.8–4.3)
XII Other and unspecified malignant neoplasms	785	0.8 (0.7–0.9)	122	0.7 (0.6–0.9)	145	0.7 (43.1–0.8)	377	1.0 (0.9–1.1)	141	0.6 (0.5–0.7)
XII(a) Other specified malignant tumors	368	0.4 (0.3–0.4)	64	0.4 (0.3–0.5)	92	0.4 (43.1–0.5)	131	0.4 (0.3–0.4)	81	0.4 (0.3–0.4)
XII(b) Other unspecified malignant tumors	417	0.4 (0.4–0.5)	58	0.3 (0.3–0.4)	53	0.2 (43.1–0.3)	246	0.7 (0.6–0.8)	60	0.3 (0.2–0.3)
Not classified by ICCC or in situ	258	0.3 (0.2–0.3)	26	0.2 (0.1–0.2)	48	0.2 (43.1–0.3)	106	0.3 (0.2–0.4)	78	0.3 (0.3–0.4)

Source: CDC's National Program of Cancer Registries and the NCI's Surveillance, Epidemiology, and End Results Program.

Abbreviations: CI = confidence interval, ICCC= International Classification of Childhood Cancer.

* Rates are per 1 million persons and age-adjusted to the 2000 U.S. Standard population.

† Cases included all malignant cancers (with behavior code = 3) as grouped by the ICCC.

¶ Incidence data are compiled from cancer registries that meet the data quality criteria for all years 2003–2014 (covering >99% of the U.S. population). Nevada is excluded. Registry-specific data quality information is available at https://www.cdc.gov/cancer/npcr/uscs/data/00_data_quality.htm.

§ Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

** Case counts <16 are suppressed.

†† ICCC group XI(e) Skin carcinomas suppressed because one region had <16 cases. Per United States Cancer Statistics complementary cell suppression rules: counts for national and regional data must be suppressed if a single state in a region or division is suppressed.